For the quarter ending 2025-09-30, BEIGF had $1,324,456K increase in cash & cash equivalents over the period. $354,469K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 124,841 | 95,590 |
| Depreciation and amortization expense | 37,284 | 68,418 |
| Share-based compensation expenses | 140,809 | 246,287 |
| Gain on deconsolidation of a subsidiary | - | 0 |
| Acquired in-process research and development | 191 | 500 |
| Amortization of research and development cost share liability | -29,275 | -45,569 |
| Impairment of equity investments | 34,216 | - |
| Other items, net | -5,533 | 15,128 |
| Accounts receivable | 93,925 | 73,369 |
| Inventories | 28,836 | -6,174 |
| Other assets | -100,563 | 45,316 |
| Accounts payable | 28,471 | -35,852 |
| Accrued expenses and other payables | 90,261 | 75,625 |
| Other liabilities | 3,486 | 64 |
| Net cash provided by (used in) operating activities | 402,553 | 307,680 |
| Purchases of property, plant and equipment | 48,084 | 100,233 |
| Purchase of intangible asset | 0 | 20,000 |
| Proceeds from sale or maturity of investments | 0 | 1,800 |
| Purchase of in-process research and development | 691 | 60,000 |
| Other investing activities | 499 | 10,113 |
| Net cash used in investing activities | -49,274 | -188,546 |
| Proceeds from other debt | 885,000 | - |
| Proceeds from long-term loan | 0 | 0 |
| Repayment of long-term loan | 4,263 | 16,799 |
| Proceeds from short-term loans | 0 | 221,521 |
| Repayment of short-term loans | 0 | 275,782 |
| Payments of withholding taxes from share-based awards | 0 | 24,195 |
| Proceeds from option exercises and employee share purchase plan | 80,535 | 96,503 |
| Other financing activities | 0 | 0 |
| Net cash provided by financing activities | 961,272 | 1,248 |
| Effect of foreign exchange rate changes, net | 9,905 | 26,957 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 1,324,456 | 147,339 |
| Cash and cash equivalents at beginning of period | 2,638,747 | - |
| Cash and cash equivalents at end of period | 4,110,542 | - |
BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)